Cost Talk: Discussing Cancer Care Costs
Cost Talk: a Randomized Stepped Wedge Trial of Interventions Helping Patients Discuss Cancer Care Costs With Clinicians During Shared Decision Making
1 other identifier
interventional
117
1 country
1
Brief Summary
The purpose of this study is to investigate whether an encounter decision aid (used during a consultation) containing cost information about options, combined with clinician training about cost discussions and available financial resources, influence surgeon-patient cost conversations, referrals to address costs, patients' financial stress, and high-quality decision-making for patients with slow-growing prostate cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable prostate-cancer
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2020
CompletedFirst Posted
Study publicly available on registry
May 21, 2020
CompletedStudy Start
First participant enrolled
June 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 2, 2022
CompletedSeptember 26, 2022
September 1, 2022
1.9 years
May 11, 2020
September 23, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Frequency of cost conversations
Immediately after the clinic or virtual visit
Initiator (surgeon, patient, or caregiver) of cost conversations
Immediately after the clinic or virtual visit
Whether or not a referral is made to address costs
Immediately after the clinic or virtual visit
Secondary Outcomes (2)
Number of patients who had a decisional conflict
Immediately after the clinic or virtual visit
Number of patients who engaged in high-quality shared decision-making - CollaboRATE
Immediately after the clinic or virtual visit
Other Outcomes (3)
Decision regret
3 month follow-up
Number of patients who had a decisional conflict
3 month follow-up
Financial toxicity
3 month follow-up
Study Arms (2)
Arm 1: Usual Care
NO INTERVENTION* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer. * Usual Care-Participating clinicians have treatment options discussion with patients with slow-growing prostate cancer. Visits are audio-recorded and/or described by patient self-report measure.
Arm 2: Option Grid
EXPERIMENTAL* Each participating urologic surgeon will begin in the usual care arm of the study. Subsequently, they will be randomized to the intervention arm at staggered time points to undergo training and begin using the Option Grid decision aid intervention with patients who are diagnosed with slow-growing prostate cancer. * Decision Aid-Participating surgeons use an encounter decision aid to discuss treatment options with patients who have slow-growing prostate cancer. Visits are audio-recorded and/or evaluated by patient self-report measure.
Interventions
-A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions
Eligibility Criteria
You may qualify if:
- At least 18 years of age
- Visiting a participating urologist/urologic surgeon to discuss treatment options
- Slow growing prostate cancer defined as Gleason score of 6 or 7 (3+4) and/or PSA (prostate-specific antigen) level less than 10ng/ml or at surgeon's discretion
- Must be patients of one of the participating providers
You may not qualify if:
- Patients who cannot give informed consent due to cognitive or emotional barriers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Related Publications (2)
Politi MC, Forcino RC, Parrish K, Durand MA, O'Malley AJ, Moses R, Cooksey K, Elwyn G. The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: Results of a stepped-wedge cluster randomised trial. Health Expect. 2023 Oct;26(5):2023-2039. doi: 10.1111/hex.13810. Epub 2023 Jul 2.
PMID: 37394739DERIVEDPoliti MC, Forcino RC, Parrish K, Durand MA, O'Malley AJ, Elwyn G. Cost talk: protocol for a stepped-wedge cluster randomized trial of an intervention helping patients and urologic surgeons discuss costs of care for slow-growing prostate cancer during shared decision-making. Trials. 2021 Jun 29;22(1):422. doi: 10.1186/s13063-021-05369-4.
PMID: 34187547DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mary Politi, Ph.D.
Washington University School of Medicine
- PRINCIPAL INVESTIGATOR
Glyn Elwyn, M.D., Ph.D., MSc
Dartmouth College
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2020
First Posted
May 21, 2020
Study Start
June 12, 2020
Primary Completion
April 20, 2022
Study Completion
July 2, 2022
Last Updated
September 26, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share